Uveal melanoma

Uveal Melanoma
ICD-10	C69.
ICD-9	190
ICD-O:	M8720/3
OMIM	155720
DiseasesDB	2614
MedlinePlus	001022
eMedicine	oph/403

WikiDoc Resources for Uveal melanoma
Articles
Most recent articles on Uveal melanoma Most cited articles on Uveal melanoma Review articles on Uveal melanoma Articles on Uveal melanoma in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Uveal melanoma Images of Uveal melanoma Photos of Uveal melanoma Podcasts & MP3s on Uveal melanoma Videos on Uveal melanoma
Evidence Based Medicine
Cochrane Collaboration on Uveal melanoma Bandolier on Uveal melanoma TRIP on Uveal melanoma
Clinical Trials
Ongoing Trials on Uveal melanoma at Clinical Trials.gov Trial results on Uveal melanoma Clinical Trials on Uveal melanoma at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Uveal melanoma NICE Guidance on Uveal melanoma NHS PRODIGY Guidance FDA on Uveal melanoma CDC on Uveal melanoma
Books
Books on Uveal melanoma
News
Uveal melanoma in the news Be alerted to news on Uveal melanoma News trends on Uveal melanoma
Commentary
Blogs on Uveal melanoma
Definitions
Definitions of Uveal melanoma
Patient Resources / Community
Patient resources on Uveal melanoma Discussion groups on Uveal melanoma Patient Handouts on Uveal melanoma Directions to Hospitals Treating Uveal melanoma Risk calculators and risk factors for Uveal melanoma
Healthcare Provider Resources
Symptoms of Uveal melanoma Causes & Risk Factors for Uveal melanoma Diagnostic studies for Uveal melanoma Treatment of Uveal melanoma
Continuing Medical Education (CME)
CME Programs on Uveal melanoma
International
Uveal melanoma en Espanol Uveal melanoma en Francais
Business
Uveal melanoma in the Marketplace Patents on Uveal melanoma
Experimental / Informatics
List of terms related to Uveal melanoma

Overview

Uveal Melanoma is cancer (melanoma) of the eye involving the iris, ciliary body, or choroid (collectively referred to as the uvea) with advanced tumors encompassing more than one of these structures. Tumors arise from the pigment cells (melanocytes) that give color to the eye. Uveal melanoma is distinct from most skin melanomas associated with ultraviolet exposure; however, it shares several similarities with other non-sun-exposed melanomas.

Incidence of uveal melanoma is highest among people with lighter skin and blue eyes. Other risk factors, such as blue light exposure and arc welding have been put forward, but are still debated in the field. The size of the tumor tends to double yearly creating pressure in the eye and often impairing peripheral vision.

Treatment

Primary treatment can involve removal of the affected eye (enucleation); however, this is now reserved for cases of extreme tumor burden or other secondary problems. Advances in radiation therapies have significantly decreased the number of patients treated by enucleation.

The most common radiation treatment is plaque brachytherapy, in which a small disc-shaped shield (plaque) encasing radioactive seeds (most often Iodine-125, though Ruthenium-106 and Palladium-103 can also be used) is attached to the outside surface of the eye, overlying the tumor. The plaque is left in place for a few days and then removed. There is no difference in risk of metastasis between enucleation and plaque radiotherapy.

Other modalities of treatment include transpupillary thermotherapy, external beam proton therapy, resection of the tumor, or rarely a combination of different modalities.

Prognosis

The primary site of metastasis for uveal melanoma is the liver in most patients, less likely the lungs. Approximately 50% of patients will develop metastases within 15 years after treatment of the primary tumor. The average survival time after diagnosis of liver metastases is 8 to 10 months.

External Links

• The See A Cure Foundation. A grassroots, patient-based, eye cancer nonprofit
• The Ocular Oncology Service
• The Eye Cancer Network
• Ocular Oncology - Bascom Palmer Eye Institute
• Mikes Page - The Melanoma Resource Center
• OCU-MEL - Ocular Melanoma e-mail list for patients, caregivers and healthcare professionals